AngioWaveNet

K244002

Angiowave Imaging, Inc. · cleared 2025-09-10 · product code QIH · Radiology

Premarket evidence — what FDA accepted

Device typesamd
source quote (p.4)
AngioWaveNet software is intended for use to enhance the visibility of blood vessels, vascular structures, and related anatomical features within angiographic images, which may be clinically useful to the treating physician
Algorithmartificial intelligence (AI) and machine learning (ML) system, neural network architecture in the form of an encoder-decoder
source quote (p.5)
AngioWaveNet is a spatio-temporal enhancement processing (STEP) is an artificial intelligence (AI) and machine learning (ML) system designed to enhance the visibility of blood vessels in angiograms using the unique spatial and temporal information contained in the frames of angiographic cines. The Angiowave STEP method employs a neural network architecture in the form of an encoder-decoder, which sequentially takes multiple contiguous frames of an angiogram as input and uses this information to provide enhanced visualization of vessels in the central frame.
Adaptive (vs locked)No
source quote (p.6)
The AI/ML model at the heart of STEP was trained on a comprehensive dataset of 300 anonymized angiograms, averaging 70 frames each, provided by a large non-profit healthcare organization that operates in Maryland and the Washington, D.C. region.
PCCPFDA source did not state this
Cybersecurity addressedYes
source quote (p.7)
For cybersecurity we provided a Cybersecurity Risk Management Report, the Threat Model, the Cybersecurity Risk Assessment, the Software Bill of Materials (SBOM), the Assessment of Unresolved Anomalies, Cybersecurity Metrics, Cybersecurity Controls, Architecture Views, Cybersecurity Testing, Cybersecurity Labeling, Cybersecurity Management Plan, and Interoperability information.

Validation studies (1)

Reader study (MRMC)

n=31 patients

endpoints: clinical decision impact; ease of visualization; processing success rate; patient-level success criteria; unresolved false positives/negatives

Reported performance (0 observations)

FDA source did not state a quantitative performance metric — non-reporting is itself the signal.

Each value carries its own analysis unit and task — never compare or pool across devices. Source: 510(k) summary PDF.

Predicate network

Postmarket — what happened after clearance

0
recalls in product code, 24mo
3
MAUDE reports in code, 12mo
vs code's own 3-yr baseline
0
drift signals on this device

Recall and MAUDE counts are product-code-level (reports aren't reliably attributable to one device). Signals are descriptive observables with sources — never a judgment that the device is unsafe or drifting. Snapshot 2026-07-08.

Reimbursement — how devices like this got paid

Not yet tracked — no payment pathway indexed for this clearance (the reimbursement corpus is a growing seed set).

RIGOR™ Precedent · public FDA/CMS data · descriptive decision-support, not regulatory or reimbursement advice. Share this page: radar.healthai.com/precedent/device/K244002